SM
ACHN

Sabby Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Sabby Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-174
Closed -$50K – 216
2017
Q4 		$50K Buy
+174
New +$632 ﹤0.01% 141
2016
Q4 		– Sell
-1,681
Closed -$1.36M – 350
2016
Q3 		$1.36M Buy
1,681
+681
+68% +$5.79K 0.05% 159
2016
Q2 		$780K Sell
1,000
-5
-0.5% -$43 0.04% 182
2016
Q1 		$776K Buy
+1,005
New +$7.36K 0.04% 177
2015
Q1 		– Sell
-296
Closed -$363 – 337
2014
Q4 		$363 Sell
296
-3,642
-92% -$44.5K 0.01% 196
2014
Q3 		$3.93K Buy
3,938
+2,261
+135% +$21K 0.15% 71
2014
Q2 		$1.27M Buy
1,677
+535
+47% +$2.13K 0.05% 129
2014
Q1 		$376K Sell
1,142
-349
-23% -$1.22K 0.02% 188
2013
Q4 		$495K Sell
1,491
-1,163
-44% -$3.38K 0.03% 152
2013
Q3 		$802K Buy
2,654
+487
+22% +$3.34K 0.05% 132
2013
Q2 		$1.77M Buy
+2,167
New +$16.5K 0.12% 95

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Sabby Management's ACHN Position: Q1 2018 in Review

Sabby Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 16,705 shares — an estimated $48K sold.

Sabby Management first reported a position in ACHN in Q3 2013 and held it in 8 quarters. The position peaked at $1.5M in Q4 2013. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Sabby Management reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Sabby Management sold 16,705 Achillion Pharmaceuticals shares in Q1 2018, an estimated $48K.
  • Sabby Management first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 8 quarters.
  • Sabby Management's Achillion Pharmaceuticals position peaked at $1.5M in Q4 2013.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.